SIRO Clinpharm, a clinical research organisation headquartered in Mumbai, India has appointed Gopakumar Menon as chief executive to build and enhance the firm’s biopharma service offering, across the US, Europe and Asia.
Menon has been working in the pharmaceutical industry for the more than 12 years in various capacities, from discovery to sales and marketing.
Prior to joining SIRO Clinpharm he worked for Boston, US-based Sciformix. He has had significant experience working with Fortune 500 companies such as Cognizant and Satyam, as well as with venture funded start-up organisations.
SIRO Clinpharm has offices in India, Malaysia, US, Israel Germany, Romania, Estonia, Greece, Czech Republic and Spain.
SIRO Clinpharm appoints chief executive
Takes responsibility for expanding business across the US, Europe and Asia
You may also like
Research & Development
€2.5m boost for SensABLATE to revolutionise real-time lung cancer treatment
The next-generation AI and photonics system is designed to provide instant intraoperative confirmation during lung cancer ablation and aims to improve precision, reduce repeat procedures and enhance patient outcomes
Regulatory
FDA grants Medivir’s MIV-711 Orphan Drug Designation for Osteogenesis Imperfecta treatment
The FDA has awarded Orphan Drug Designation to Medivir’s selective cathepsin K inhibitor MIV-711 for Osteogenesis Imperfecta, a rare genetic bone disorder, after preclinical and clinical data suggests the therapy may strengthen bone
Research & Development
Vivan Therapeutics and MRC LMS launch partnership to study how KRAS mutations, diabetes and diet shape cancer drug response
The new collaboration will investigate how KRAS mutations and metabolic conditions such as diabetes influence chemotherapy effectiveness, using high-throughput in vivo “fly avatar” models